化合物 Vabicaserin hydrochloride,Vabicaserin hydrochloride

化合物 Vabicaserin hydrochloride|T13275|TargetMol

价格 592 1550 2270
包装 1mg 5mg 10mg
最小起订量 1mg
发货地 上海
更新日期 2025-11-17
QQ交谈 微信洽谈

产品详情

中文名称:化合物 Vabicaserin hydrochloride英文名称:Vabicaserin hydrochloride
CAS:887258-94-8品牌: TargetMol
产地: 美国保存条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
纯度规格: 98.42%产品类别: 抑制剂
货号: T13275
2025-11-17 化合物 Vabicaserin hydrochloride Vabicaserin hydrochloride 1mg/592RMB;5mg/1550RMB;10mg/2270RMB 592 TargetMol 美国 Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. 98.42% 抑制剂

Product Introduction

Bioactivity

名称Vabicaserin hydrochloride
描述Vabicaserin hydrochloride (SCA 136) is a selective agonist of 5-hydroxytryptamine 2C (5-HT2C) receptor (EC50: 8 nM).
体外活性In Chinese hamster ovary cell membranes, Vabicaserin displaces 125I-(2,5-dimethoxy)phenylisopropylamine binding from human 5-HT2C receptor sites (Ki: 3 nM) and is >50-fold selective over a number of serotonergic, noradrenergic, and dopaminergic receptors. The binding affinity determined for the human 5-HT2B receptor subtype using [3H]5HT is 14 nM. Vabicaserin is a potent and full agonist (EC50, 8 nM; Emax, 100%) in stimulating 5-HT2C receptor-coupled calcium mobilization and exhibits 5-HT2A receptor antagonism and 5-HT2B antagonist or partial agonist activity in transfected cells, depending on the level of receptor expression. Vabicaserin showed a lower affinity at the binding site (22 nM) of 5-HT2C antagonist labeled with [3H]methsulamide. Other binding studies have shown that Vabicaserin has an affinity for 5-HT2B and 5-HT1A receptors with Ki values of 14 and 112 nM, respectively [1].
体内活性The unchanged drug represents less than 19, 20, and 35% of total plasma radioactivity at all the time points examined in mice, rats, and dogs, respectively, after a single oral dose of [14C]Vabicaserin at 50, 5, and 15 mg/kg. The carbamoyl glucuronide (CG) represents approximately 7 to 36% of plasma radioactivity in mice and 2 to 28% of plasma radioactivity in dogs but is not detected in rat plasma after the single [14C]Vabicaserin dose. However, the CG is observed in rat plasma after multiple-dose administration of Vabicaserin at higher doses, and the CG is approximately 20 times less than Vabicaserin based on steady-state AUC0-24 values. The estimated plasma AUC0-24 ratios of CG to the parent drug are 1.5 and 1.7 in mice and dogs after the single [14C]Vabicaserin dose, respectively. The plasma AUC0-24 ratios for the CG to Vabicaserin at steady-state with doses used for safety assessment are less for mice (0.2-0.6) and slightly higher for dogs (1.8-4.0) compared with the single-dose values. The CG is detected in dog urine in similar amounts to the parent drug, although it is not detected in mouse or rat urine after the single [14C]Vabicaserin dose. Radioactivity in a 0- to 24-h bile collection from rats receiving a 5 mg/kg [14C]Vabicaserin dose accounts for 19 and 24% of the administered dose in males and females, respectively. Although the CG is not detected in the urine or feces of rats after a single oral administration, In male rats and 15% in female rats, it represents an average of up to 30% of biliary radioactivity. In monkeys after a single oral 25-mg/kg dose of Vabicaserin, the plasma concentrations of the CG exceeded those of Vabicaserin at all the time points (2-24 h) postdose, although the amount of CG relative to Vabicaserin decreased by 24 h postdose, with ratios of 17.5 at 2 h and 1.7 at 24 h.In monkeys, The CG to Vabicaserin AUC0-24 ratio of 12:1 indicates that the CG is a major metabolite [2].
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
溶解度DMSO : 55 mg/mL (207.71 mM), Sonication is recommended.
H2O : 4 mg/mL (15.11 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.55 mM), Sonication is recommended.
关键字Vabicaserin Hydrochloride | Vabicaserin hydrochloride | Vabicaserin | Serotonin Receptor | SCA-136 | SCA136 | Inhibitor | inhibit | 5-hydroxytryptamine Receptor | 5HTReceptor | 5-HT2C Receptor | 5-HT2C | 5-HT Receptor | 5HT Receptor
相关产品Cinchonidine | D-Menthol | Cloperastine hydrochloride | Alverine citrate | Amitriptyline hydrochloride | Olanzapine | Dapoxetine hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Fluoxetine hydrochloride | Serotonin hydrochloride | Clozapine N-Oxide
相关库经典已知活性库 | 已知活性化合物库 | 神经信号分子库 | NO PAINS 化合物库 | GPCR靶点分子库 | 临床期小分子药物库 | 膜蛋白靶向化合物库 | 神经退行性疾病化合物库 | 药物功能重定位化合物库 | 疼痛相关化合物库 | 抗癌临床化合物库 | 抗癌药物库
关键字: SCA 136|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。
成立日期 2013-04-18 (13年) 注册资本 566.265100万人民币
员工人数 100-500人 年营业额 ¥ 1亿以上
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务 经营模式 贸易,工厂,试剂,定制,服务
  • TargetMol中国(陶术生物)
VIP 4年
  • 公司成立:13年
  • 注册资本:566.265100万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:小分子抑制剂、药物筛选化合物库、药物筛选等
  • 公司地址:静安区江场三路238号8楼
询盘

化合物 Vabicaserin hydrochloride|T13275|TargetMol相关厂家报价

产品名称 价格   公司名称 报价日期
询价
VIP4年
湖北魏氏化学试剂股份有限公司
2025-09-18
询价
VIP4年
湖北威德利化学试剂有限公司
2025-08-11
询价
VIP4年
西安齐岳生物科技有限公司
2025-11-11
询价
VIP4年
湖北魏氏化学试剂股份有限公司
2025-09-18
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.